Safety experience with caspofungin in pediatric patients
Zaoutis, Theoklis × Lehrnbecher, Thomas Groll, Andreas H Steinbach, William J Jafri, Hasan S Maertens, Johan Ngai, Angela L Chow, Joseph W Taylor, Arlene F Strohmaier, Kim M Bourque, Michael Bradshaw, Susan K Petrecz, Maria Kartsonis, Nicholas A #
Williams & Wilkins
The Pediatric Infectious Disease Journal vol:28 issue:12 pages:1132-1135
We analyzed the caspofungin safety experience in 5 clinical registration studies in 171 pediatric patients, 1 week to 17 years of age. Caspofungin was administered for 1 to 87 (mean 12.1) days. The most common drug-related adverse events were fever, increased AST, increased ALT, and rash; few events were serious or required treatment discontinuation. Caspofungin was well tolerated in this pediatric population.